Inflammatory infiltrate of tumors
| Tumor infiltrating hematopoetic cells (%)* . | d10 . | d13 . | d18 . | |||
|---|---|---|---|---|---|---|
| Control . | Th1 cell treated . | Control . | Th1 cell treated . | Control . | Th1 cell treated . | |
| CD4 | 2.6 | 9.7 | 3.4 | 13.3 | 0.7 | 11.5 |
| CD11b | 1.0 | 1.4 | 2.1 | 3.1 | 0.7 | 2.2 |
| CD8 | 0.1 | 0.4 | 0.9 | 1.3 | 2.7 | 0.5 |
| F4/80 | 0.6 | 0.1 | 0.7 | 0.1 | 0.2 | 0.2 |
| CD11c | 1.5 | 1.3 | 1.4 | 0.8 | 1.9 | 0.9 |
| Tumor infiltrating hematopoetic cells (%)* . | d10 . | d13 . | d18 . | |||
|---|---|---|---|---|---|---|
| Control . | Th1 cell treated . | Control . | Th1 cell treated . | Control . | Th1 cell treated . | |
| CD4 | 2.6 | 9.7 | 3.4 | 13.3 | 0.7 | 11.5 |
| CD11b | 1.0 | 1.4 | 2.1 | 3.1 | 0.7 | 2.2 |
| CD8 | 0.1 | 0.4 | 0.9 | 1.3 | 2.7 | 0.5 |
| F4/80 | 0.6 | 0.1 | 0.7 | 0.1 | 0.2 | 0.2 |
| CD11c | 1.5 | 1.3 | 1.4 | 0.8 | 1.9 | 0.9 |
Tumors (n = 10/group) from days 10, 13, and 18 after tumor cell injection were excised from mice, homogenized, and single cells were stained for different cell types; 30 000 cells were acquired on the LSRII.
d indicates day.
Total living cells were gated and the percentage of infiltrating cells were calculated on the basis of 10 000 cells.